Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EBV mRNA Vaccine for the Prevention of EBV-Related Diseases After Allogeneic Hematopoietic Stem Cell Transplantation
NCT07674199Phase 1Not yet recruiting
- Sponsor
- General Hospital of Western Theater Command of PLA
- Start
- Jun 2026
- Primary completion
- Dec 2030
- Countries
- 1
01
Overview
Phase 1, open-label trial of WGc-0401 in Epstein-Barr virus infection (2 arms), sponsored by General Hospital of Western Theater Command of PLA. Primary endpoints: Incidence of grade III-IV acute graft-versus-host disease at 100 days and Incidence of grade >=3 treatment related adverse events at 180 days. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
WGc-0401
03
Conditions
Epstein-Barr virus infection
Beyond the preview
Go deeper on NCT07674199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07674199.